

2025 #23

July 28, 2025

INSIDE:

ABC Welcome Letter to CBER Director Highlights Unnecessary and Burdensome Regulations Impacting Community Blood Centers.....	2
WORD IN WASHINGTON	3
BRIEFLY NOTED.....	5
Register for the August 7th ABC Advocacy Forum ..	6
Save the Date: SMT Journal Club Webinar on August 29th	6
Register for the July ABC Webinar: "Emerging Infectious Diseases & Malaria Risks: Updates for Blood Centers"	6
ABC Economic Outlook Survey Report Available	6
Full Schedule Available for 2025 ADRP Master Class September 24th- 25th	6
2025 ADRP Annual Conference Compendium Available..	7
SAVE THE DATE: ABC WELC Rise & Lead Workshop November 13th-14th	7
MEMBER NEWS.....	7
GLOBAL NEWS	8
CALENDAR.....	8
POSITIONS.....	9

FDA Publishes Draft Guidance Eliminating Requirement for HBsAg Testing

The U.S. Food and Drug Administration (FDA) recently [released](#) a draft guidance titled "Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen (HBsAg)." The draft guidance proposes removing the requirement for testing blood donations for HBsAg. The recommendation is based on scientific evidence indicating that the risk of hepatitis B virus (HBV) transmission is appropriately reduced by the other two tests currently required for HBV.

This proposed change is a significant victory for community blood centers and [aligns](#) with America's Blood Centers' (ABC) long-standing advocacy efforts, most recently its inclusion in a [letter](#) to the U.S. Department of Health and Human Services (HHS) outlining opportunities to reduce burdens on blood centers while maintaining the highest standards of blood safety. The elimination of HBsAg testing could save blood centers an estimated \$15 to \$22.5 million annually, allowing community blood centers to operate more efficiently while maintaining the safety and availability of the nation's blood supply.

The draft guidance states that, "when donations of blood and blood components are tested for HBV DNA and antibody to hepatitis B core antigen (anti-HBc) using screening tests that FDA has licensed, approved, or cleared for such use, in accordance with the manufacturer's instructions, FDA believes that testing of the donations for HBsAg is not necessary to comply with 21 CFR 610.40(b)." According to available scientific data, the risk of HBV transmission by blood and blood components is appropriately reduced by testing blood donations for HBV DNA and anti-HBc. This recommendation does not apply to source plasma, and centers must continue to follow their, "standard operating procedures for testing source plasma for HBV."

Once this draft guidance is finalized, "blood establishments that discontinue testing donations for HBsAg should revise their *Circular of Information* to remove the statement that donations are nonreactive for HBsAg." Additionally, this change is considered a minor change, meaning blood centers, "must report the change in [their] annual report."

ABC Chief Executive Officer (CEO) Kate Fry, MBA, CAE explained in a statement, "ABC applauds the FDA for taking this evidence-based step towards streamlining blood donation testing requirements. We call upon FDA to continue to examine options to remove unnecessary, outdated, and burdensome requirements

(continued on page 2)



FDA Publishes Draft Guidance Eliminating Requirement for HBsAg Testing (continued from page 1)

on blood centers, including other testing requirements that fail to increase the safety of the nation's blood supply.”

ABC intends to submit [comments](#) in response to the draft guidance by the October 14th deadline. Please contact ABC's Director of Regulatory Affairs and Public Policy [Justine Coffey, JD, LLM](#) if you would like to share input or if you have any questions. ABC will continue to provide updates on its advocacy efforts as they become available.

(Sources: FDA [Draft Guidance](#), 7/15/25; ABC [Statement](#), 7/15/25) ♦

ABC Welcome Letter to CBER Director Highlights Unnecessary and Burdensome Regulations Impacting Community Blood Centers

America's Blood Centers (ABC) has sent a [letter](#) to the U.S. Food and Drug Administration's (FDA) Chief Medical and Scientific Officer in the Office of the Commissioner and Center for Biologics Evaluation and Research (CBER) Director Vinayak Prasad, MD, MPH welcoming him to the role and expressing support for deregulatory changes proposed in the [release](#) of the FDA draft guidance titled “Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen: Draft Guidance for Industry.” Specifically, the July 25th letter highlighted 12 recommendations outlined and prioritized by ABC in [comments](#) previously submitted to the U.S. Department of Health and Human Services (HHS) regarding regulations and guidance that ABC urged the agency to modify or repeal in response to a Request for Information (RFI) to identify and eliminate outdated or unnecessary regulations.

ABC explained in the letter that, “[we support] the Administration's efforts to identify burdensome and inefficient regulations. Unnecessary regulation adds cost and complexity, making it harder for blood centers to ensure every patient's need for blood is met without impacting the safety of the blood supply...We appreciate that under your leadership, the first of these deregulatory changes is already underway with the release of the ‘Recommendations for Testing Blood Donations for Hepatitis B Surface Antigen: Draft Guidance for Industry’ [and we] respectfully request an opportunity to meet to discuss the deregulatory opportunities outlined in our letter and look forward to working with you to ensure a safe and available blood supply.” ABC will continue to provide updates on its advocacy efforts as they become available. Please [contact](#) ABC's Director of Regulatory Affairs and Public Policy Justine Coffey, JD, LLM with questions or comments.

(Source: ABC [Letter](#), 7/25/25) ♦

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2025 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry
Chief Medical Officer: Jed Gorlin
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$420

Send subscription queries to memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

WORD IN WASHINGTON



The U.S. Food and Drug Administration (FDA) has [announced](#) that George Francis Tidmarsh, MD, PhD has been named director of the Center for Drug Evaluation and Research (CDER). In this role, he will be responsible for leading, “FDA’s efforts to ensure safe, effective, and high-quality drugs are available to the American people.” According to his [bio](#), “Dr. Tidmarsh brings over 30 years of experience in biotechnology, clinical medicine, and regulatory science [to FDA] and has authored 143 scientific publications and patents. [He] joined the FDA from Stanford University’s School of Medicine where he was adjunct professor [of] Pediatrics and Neonatology. [Dr. Tidmarsh] served as clinical faculty at Stanford for a number of years prior to devoting his career to clinical research and development, working to bring new treatments to patients. [He has led] the successful clinical development of seven FDA-approved drugs and served as founder and chief executive officer of multiple biopharmaceutical companies focused on oncology and critical care medicine and is widely recognized for his ability to bring forward innovative treatments that address serious unmet medical needs. [Dr. Tidmarsh] earned his medical degree and doctorate in cancer biology from Stanford, where he completed his residency training in pediatrics. He went on to complete two subspecialty programs at Stanford, one in pediatric oncology and another in neonatology.”

(Source: FDA [Announcement](#), 7/21/25)

The Senate Health, Education, Labor, and Pensions (HELP) Committee has [advanced](#) the nomination of Brian Christine as assistant secretary for Health at the U.S. Department of Health and Human Services (HHS) to the full Senate following a July 16th hearing. Dr. Christine is a urologic surgeon at Urology Centers of Alabama.

(Source: Senate HELP Committee [Announcement](#), 7/24/25)

The Centers for Medicare & Medicaid Services (CMS) has [expanded access](#) to advanced therapies to treat sickle cell disease (SCD) as, “33 states, plus the District of Columbia and Puerto Rico, will participate in the Cell and Gene Therapy (CGT) Access Model, a bold new approach to delivering cutting-edge treatments for people on Medicaid living with SCD.” According to the agency announcement, “led by the CMS Innovation Center, the model is the first time the federal government has negotiated outcomes-based agreements with CGT manufacturers on behalf of state Medicaid agencies. Under the model, participating states receive guaranteed discounts and rebates from participating CGT manufacturers if the therapies fail to deliver their promised therapeutic benefits.” Key features of the model are:

- “CMS-negotiated outcomes-based contracts with manufacturers, developed with input from state Medicaid agencies, patients, and providers;
- [o]ptional federal support of up to \$9.55 million per state to help with implementation, outreach, and data tracking;
- [f]lexible start dates between January 2025 and January 2026 for participating states; [and]
- [p]otential future expansion to cover other diseases with high-cost, high-impact therapies.”

(Source: CMS [Announcement](#), 7/15/24)

The Administration has [announced](#) an artificial intelligence (AI) action plan. According to an announcement from the White House, the plan titled “[Winning the AI Race: America’s AI Action Plan](#)” includes the identification of, “over 90 Federal policy actions across three pillars — ‘Accelerating Innovation,’ ‘Building American AI Infrastructure,’ and ‘Leading in International Diplomacy and Security’ — that the Trump Administration will take in the coming weeks and months.” Several key policies include:

(continued on page 4)



WORD IN WASHINGTON (continued from page 3)

- *“Exporting American AI:* [t]he Commerce and State Departments will partner with industry to deliver secure, full-stack AI export packages — including hardware, models, software, applications, and standards — to America’s friends and allies around the world;
- *Promoting Rapid Buildout of Data Centers:* [e]xpediting and modernizing permits for data centers and semiconductor fabs, as well as creating new national initiatives to increase high-demand occupations like electricians and HVAC technicians;
- *Enabling Innovation and Adoption:* [r]emoving onerous federal regulations that hinder AI development and deployment, and seek private sector input on rules to remove; [and]
- *Upholding Free Speech in Frontier Models:* [u]pdating federal procurement guidelines to ensure that the government only contracts with frontier large language model developers who ensure that their systems are objective and free from top-down ideological bias.”

(Source: White House [Announcement](#), 7/23/25)

HHS has [announced](#), “a major initiative to begin reforming the organ transplant system following an investigation by its Health Resources and Services Administration (HRSA) that revealed disturbing practices by a major organ procurement organization.” According to the HHS news release, “HRSA examined 351 cases where organ donation was authorized, but ultimately not completed. It found:

- 103 cases (29.3 percent) showed concerning features, including 73 patients with neurological signs incompatible with organ donation;
- [a]t least 28 patients may not have been deceased at the time organ procurement was initiated — raising serious ethical and legal questions; [and]
- [e]vidence pointed to poor neurologic assessments, lack of coordination with medical teams, questionable consent practices, and misclassification of causes of death, particularly in overdose cases.”

In response to the findings, HHS Secretary Robert F. Kennedy, Jr. explained in the news release that he will, “[decertify](#) the federally-funded organ procurement organization (OPO) if it fails to comply with [corrective] action requirements.” He added that, “HHS is restoring integrity and transparency to organ procurement and transplant policy by putting patients’ lives first. These reforms are essential to restoring trust, ensuring informed consent, and protecting the rights and dignity of prospective donors and their families.” Corrective measures for OPO include, “system-level changes to safeguard potential organ donors nationally. The OPO must conduct a full root cause analysis of its failure to follow internal protocols — including noncompliance with the five-minute observation rule after the patient’s death — and develop clear, enforceable policies to define donor eligibility criteria. Additionally, it must adopt a formal procedure allowing any staff member to halt a donation process if patient safety concerns arise. [Also,] data about any safety-related stoppages of organ donation called for by families, hospitals, or OPO staff must be reported to regulators, and the Organ Procurement and Transplantation Network (OPTN) must update policies to strengthen organ procurement safety and provide accurate, complete information about the donation process to families and hospitals.”

(Source: HHS [Announcement](#), 7/21/25)

HHS Secretary Kennedy and Secretary of State Marco Rubio issued a joint [statement](#) on July 18th of, “formal rejection by the U.S. of the 2024 International Health Regulations (IHR) Amendments by the World Health Organization (WHO).” According to the statement, “[t]he amended IHR would [have given] the WHO the ability to order global lockdowns, travel restrictions, or any other measures it sees fit to respond to nebulous ‘potential public health risks.’ These regulations [were] set to become binding if not rejected by July 19th, 2025, regardless of the U.S.’ withdrawal from the WHO.”

(Source: HHS [Announcement](#), 7/18/25) 💧



BRIEFLY NOTED

The Cybersecurity & Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), the U.S. Department of Health and Human Services (HHS), and the Multi-State Information Sharing and Analysis Center (MS-ISAC) have published a joint cybersecurity [advisory](#) regarding Interlock ransomware activity. The communication from the agencies aims to, “help protect businesses and critical infrastructure organizations in North America and Europe against Interlock ransomware. Th[e] advisory highlights known Interlock ransomware indicators of compromise and tactics, techniques, and procedures identified through recent FBI investigations.” Actions outlined in the advisory that organizations can take to mitigate Interlock ransomware threat activity include:

- “[p]reventing initial access by implementing domain name system filtering and web access firewalls and training users to spot social engineering attempts;
- [m]itigating known vulnerabilities by ensuring operating systems, software, and firmware are patched and up to date;
- [s]egmenting networks to restrict lateral movement from initial infected devices and other devices in the same organization; [and]
- [i]mplementing identity, credential, and access management policies across the organization and then requiring multifactor authentication for all services to the extent possible.”

(Source: CISA, FBI, HHS, and MS-ISAC [Joint Cybersecurity Advisory](#), 7/22/25)

Microsoft has [issued](#) an update and expanded analysis of the “attacks against on-premises SharePoint servers that exploit CVE-2025-49706, a spoofing vulnerability, and CVE-2025-49704, a remote code execution vulnerability.” According to the company, “[t]hese vulnerabilities affect on-premises SharePoint servers only and do not affect SharePoint Online in Microsoft 365. Microsoft has released new comprehensive security updates for all supported versions of SharePoint Server (Subscription Edition, 2019, and 2016) that protect customers against these new vulnerabilities. Customers should apply these updates immediately to ensure they are protected.”

(Source: Microsoft [Announcement](#), 7/23/25)

An article [published](#) by *NPR* highlights research and advancements in the development of blood substitutes. The story explores ongoing animal trials in the U.S. and optimism that human trials could begin in the U.S. “within the next two years.” It reports on the work of researchers at the University of Maryland School of Medicine led by Dr. Allan Doctor who make, “synthetic blood from hemoglobin, the protein that nourishes the body with oxygen. The researchers extract hemoglobin from expired blood and enclose the protein in a bubble of fat, essentially creating artificial red blood cells. The protective bubble is the innovation that [they think] will solve the safety problems caused by other attempts at making synthetic blood. These other efforts also used hemoglobin, but exposed hemoglobin can be toxic to organs.”

(Source: NPR, “[Scientists are developing artificial blood that could save lives in emergencies](#),” 7/24/25) 💧





America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Register for the August 7th ABC Advocacy Forum

Registration is open for the America's Blood Centers (ABC) Advocacy Forum webinar: "How to Host an Advocacy Focused Meeting or Tour in Your Blood Center." This webinar will be held at 2 p.m. EDT on Thursday, August 7th as ABC members will gain insights on how to advocate within your blood center, how to coordinate with Congressional offices, what asks you should make, and best practices to further grow the relationship." ABC staff will also provide new and updated advocacy resources that blood centers can use to best prepare for these kinds of events. Additional information and a link to registration are available to ABC members [here](#). Please [contact us](#) with any questions.

Save the Date: SMT Journal Club Webinar on August 29th

The next ABC Scientific, Medical, and Technical (SMT) Journal Club webinar will take place on August 29th. The webinar is free to all ABC members. An email announcement with a registration link and the articles to be reviewed on the webinar will be available soon. A Continuing Medical Education (CME) credit (1.0) is now offered for all ABC SMT Journal Club webinars.

Register for the July ABC Webinar: "Emerging Infectious Diseases & Malaria Risks: Updates for Blood Centers"

Registration is open for the Tuesday, July 29th ABC Webinar: "Emerging Infectious Diseases & Malaria Risks: Updates for Blood Centers." This event will take place at 3 p.m. EDT and featured speakers include ABC Chief Medical Officer Jed Gorlin, MBA, MD and OneBlood Chief Medical Officer Rita Reik, MD, FCAP. Additional information and a link to registration are available to ABC members [here](#). Please [contact us](#) with any questions.

ABC Economic Outlook Survey Report Available

America's Blood Centers (ABC) recently announced that the ABC Economic Outlook Survey Report has been released. The report is complimentary to participants and instructions on accessing it have been distributed to the designated contact. Non-participating ABC members [may purchase the report](#). The ABC Economic Outlook Survey provides a comprehensive look at blood center finances, including 19 of the most frequently used ratios for benchmarking the financial health of an organization as well as median service fees for 30 different blood products and blood center procedures. Please [contact us](#) with questions.

Full Schedule Available for 2025 ADRP Master Class September 24th-25th

[Register](#) for the [2025 ADRP Master Class](#) taking place September 24th-25th. The [complete two-day schedule](#) has now been released. This year's theme is "Building Brighter Experiences: Empowering Customers, Engaging Employees." In today's competitive market, organizations that prioritize both employee and customer experience gain a significant edge. A motivated and engaged workforce leads to improved customer

(continued on page 7)



INSIDE ABC (continued from 6)

interactions, higher satisfaction, and long-term brand loyalty. The customer experience starts with the employee experience. This year's day 1 keynote speaker is Janice Honeycutt Herring, a former Regional Director of Operations, United Blood Services, now Vitalant. With 30+ years of experience in organizational change and leadership development, Janice will bring unparalleled insights to the blood banking industry. She is the founder and chief executive officer of Firecracker Leadership. Stay tuned for more information! Please [contact us](#) with questions.

2025 ADRP Annual Conference Compendium Available

ADRP has released the *2025 ADRP Annual Conference Compendium*. This resource is designed to help distill key insights from the conference's sessions, serving as a unique tool to assist you with topics such as data-driven mobile collections, innovative donor registration approaches, artificial intelligence- (AI) powered social media strategies, and much more. Other highlights include detailed case studies; think tank summaries; and the latest trends in donor relations. A link to download the complimentary compendium has been emailed to conference attendees ([contact us](#) if you did not receive it). Those who did not attend the 2025 ADRP Annual Conference may [purchase the compendium](#). Whether you're new to blood banking or an experienced professional, the compendium is an essential tool for any blood center professional looking to optimize their center's operations and make a greater impact.

SAVE THE DATE: ABC WELC Rise & Lead Workshop November 13th-14th

Rise & Lead

A WOMEN'S LEADERSHIP WORKSHOP

ABC is excited to announce that the 2025 ABC Women's Executive Leadership Community (WELC) [Rise & Lead Workshop](#) will take place November 13th-14th in San Antonio, Texas at the Westin Riverwalk. [Book now](#) to secure

the discounted rate. Registration will open in August. This workshop is designed for women in leadership positions, emerging leaders, and professionals seeking personal and professional growth. It also welcomes individuals who want to cultivate diverse perspectives. Attendees will engage in an intimate, engaging, and interactive environment focused on networking, mentorship, and meaningful discussions on leadership and growth. Please [contact us](#) with questions. 💧

MEMBER NEWS



LifeSouth Community Blood Centers has announced the relocation of its components manufacturing lab and hospital services to their newly constructed production and logistics building in Gainesville, Fla. According to an announcement from the blood center, "[t]he newly built, 11,600 square-foot facility expands LifeSouth's existing headquarters campus and introduces a modern, consolidated space designed to enhance operations. The new building integrates manufacturing, hospital distribution, and technical capabilities with direct access to specialized laboratories, including those focused on cellular therapies." LifeSouth Community Blood Centers President and Chief Executive Officer and America's Blood Centers President Kim Kinsell, JD, MBA explained in the announcement, "[a]s we grow, we continue to create and improve our infrastructure to meet the needs of our hospitals and for the benefit of patients in our communities. By increasing the size of our headquarters location, we are bringing our shipping, laboratories, components, and cell therapy teams together under one roof, allowing us to expand our capabilities."

(Source: LifeSouth Community Blood Centers Announcement, 7/25/25) 💧

GLOBAL NEWS

The World Health Organization (WHO) has [published](#) a policy brief titled “Policy Considerations for Strengthening Preparedness and Response to Arbovirus Epidemics and Pandemics.” According to the agency, the policy brief aims to, “[build] on the health emergency preparedness [by advocating] for an integrated approach to arbovirus epidemic and pandemic planning. It outlines policy actions aimed at building and strengthening national and subnational capacities for preparedness and response planning to address key challenges observed during past arbovirus epidemics. The document provides actionable strategic recommendations that countries can implement immediately to enhance their preparedness to arbovirus threats. It is designed for use by stakeholders across different sectors at national, regional, and global levels, including policymakers and technical officers from ministries of health, environment, agriculture, education, and other relevant sectors, as well as partners engaged in arbovirus preparedness and response efforts.” Recommendations include:

- “emergency coordination;
- collaborative surveillance systems;
- community protection;
- clinical diagnostics and care; and
- “access to countermeasures.”

(Source: WHO [Policy Brief](#), 7/16/25)

The European Blood Alliance and the International Society of Blood Transfusion (ISBT) are [holding](#) the 3rd Rare Blood Provision Workshop hosted by Osakidetza (the Basque Center for Transfusion and Human Tissue), in Bilbao, Spain from September 30th- October 1st. Registration is open and the meeting is designed for, “staff from public or non-profit blood establishments, reference laboratories, and national health systems who are directly involved or interested in rare blood provision. The event is intended as a peer-to-peer exchange and not open to industry representatives.” Both in-person and virtual attendance options are available.

(Source: EBA & ISBT Announcement, 7/24/25) ♦

CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

2025

July 29. **America’s Blood Centers (ABC) Webinar: “Emerging Infectious Diseases & Malaria Risks: Updates for Blood Centers.”** A link to registration and more information are available to ABC members [here](#).

August 7. **ABC Advocacy Forum Webinar: “How to Host an Advocacy Focused Meeting or Tour in Your Blood Center.”** A link to registration and more information are available to ABC members [here](#).

August 29. **ABC Scientific, Medical, and Technical (SMT) Journal Club Webinar.** More information will be available soon.

Sept. 10-12. **6th European Conference on Donor Health and Management (ECDHM).** Wijk aan Zee, the Netherlands. [Registration](#) is open. More information available [here](#).

(continued on page 9)

CALENDAR (continued from page 8)

Sept. 17-19. **58th Annual Conference of the German Society for Transfusion Medicine and Immunohematology (DGTI). Mannheim, Germany.** [Registration](#) is open. More information is available [here](#).

Sept. 24-25. **2025 ADRP Master Class: “Building Brighter Experiences: Empowering Customers, Engaging Employees (Virtual).** [Registration](#) is open. More information is available [here](#).

Sept. 30-Oct. 1. **3rd Annual European Blood Alliance (EBA) and the International Society of Blood Transfusion (ISBT) Rare Blood Provision Workshop. Bilbao, Spain.** [Registration](#) is open. More information is available [here](#).

Oct. 12-15. **American Association of Tissue Banks (AATB) Annual Meeting. Atlanta, Ga.** [Registration](#) is open. More information available [here](#).

Oct. 14-15. **International Protein Forum. Old Town Alexandria, Va.** [Registration](#) is open. More information is available [here](#).

Oct. 25-28. **AABB Annual Meeting. San Diego, Calif.** [Registration](#) is open. More information is available [here](#).

Oct. 26-29. **Blood 2025 and the ISBT 36th Regional Congress. Perth, Australia.** More information available [here](#).

Nov. 12. **2025 ADRP International Showcase.** More information is coming soon.

Nov. 13-14. **2025 ABC Women’s Executive Leadership Community (WELC) Rise & Lead Workshop.** More information available [here](#).

Nov. 13-14. **EBA Benchmarking Workshop. Amsterdam, Netherlands.** More information is coming soon.

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting. Atlanta, Ga.** [Registration](#) is open. More information available [here](#).

2026

Feb. 11-12. **4th Biennial International Plasma and Fractionation Association (IPFA) & EBA Symposium on Plasma Collection and Supply. Leuven, Belgium.** More information is available [here](#).

Mar. 9-12. **2026 ABC Annual Meeting. Tucson, Ariz.** More information is coming soon.

May 12-14. **2026 ADRP Annual Conference. Minneapolis, Minn.** More information is coming soon. 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Manager, Regional Development. Be part of something bigger; change the world with us by joining **ImpactLife’s team.** We are seeking a **Manager, Regional Development,** to lead donor engagement and blood drive development efforts across Central Illinois. In this key leadership role, you’ll guide a dynamic regional team in growing our mission to connect donors and patients through life-saving blood collections. This role requires

direct supervision of a regional team. This position can be located at our Peoria, Springfield, or Urbana, Illinois locations. For more information including job details, benefits, and compensation click here: [Change the World With Us.](#)

(continued on page 10)

POSITIONS (continued from page 9)

Cell Therapy Technologist (Carter BloodCare). The Cell Therapy Technologist 1 (CTT1) participates in activities in the Cellular Therapy Laboratory. These activities include, but may not be limited to, cellular therapy (CT) processing, performing and troubleshooting quality control of reagents and equipment, participating in educational instruction of students and new employees, familiarity and full compliance with all CT and general laboratory regulations, and participating in design and implementation of new methodology for processing CT products. A CTT1 ensures daily operations within the department meet and follow all established guidelines and provide excellence in service and patient care. Ability to work a flexible schedule, long and/or odd hours with little notice. Regular full-time attendance is required during normal working hours. This position requires a valid driver's license. **Education:** MT (ASCP), MLS(ASCP) or equivalent, or eligible with certification obtained within 90 days of hire. Bachelor of Science Degree in Clinical Laboratory Science, Medical Laboratory Science, Medical Technology, or a related field in laboratory science. **Experience:** Minimum of one year of experience as an MT/MLS. Equal Opportunity Employer: Disability/Veteran. Apply at www.carterbloodcare.org, click Careers & search for job Cell Therapy Tech or Cell Therapy Technologist.

Instructor – Phlebotomy (Carter BloodCare). Under the direction of the Education Coordinator, the Instructor is responsible for the training and continuing education of the Collection Services staff in all procedures involved in the blood collection process (i.e., medical history, donor lookup, phlebotomy, quality control, apheresis, CPR). This position ensures trainees receive applicable clinical experience, safely perform all required skills, and successfully complete competency testing. The Instructor plans for and guides the learning process to help students achieve the objectives required within the allotted time. This position maintains open communication with supervisory staff and informs them of employee progress. This position creates schedules, inputs data, and runs reports. Adequate transportation is necessary to travel to and from all donor centers/mobile drives to perform competency evaluations and retraining in a timely and efficient manner. This position adheres to all regulations and requirements set forth by the Food and Drug Administration (FDA), American Association of Blood Banks (AABB), CBC, and departmental policies and procedures. This position must be available to work any shift, including nights and weekends. Regular full-time attendance is required during normal working hours. **Education:** High School Diploma or equivalent. **Experience:** Six (6) months of supervisory experience required. Minimum of one year of blood banking, preferred. Six (6) months of apheresis experience, preferred. Teaching experience (professional and informal), preferred. Equal Opportunity Employer: Disability/Veteran. Apply at

www.carterbloodcare.org, click Careers & search for job #49098.

Vice President, Divisional Operations (Rhode Island Blood Center). Rhode Island Blood Center is looking for a strategic, results driven Divisional Vice President to join our leadership team. This key leadership role will oversee the blood collection operations in Rhode Island while ensuring alignment with New York Blood Center Enterprise (NYBCe) strategy. This leader will optimize performance through local teams, leveraging enterprise resources to meet collection targets, enhance donor recruitment, cultivate corporate and community relationships, and maintain regulatory compliance. A strong community connection and deep knowledge of divisional dynamics are critical to success in this role. The Divisional Vice President will ensure seamless communication within the division and collaboration across the enterprise. We offer competitive pay and a comprehensive benefits package. For a complete listing of required qualifications and to apply, click [here](#) to visit our careers page.

Donor Recruitment Manager. Vitalant is seeking a results-driven, customer-focused, and business-minded **Donor Recruitment Manager** to play a vital role in our community while significantly contributing to our life-saving mission. Your impact as a Donor Recruitment Manager is vital. You will contribute to Vitalant's life-saving mission by overseeing the donor-recruitment team to successfully achieve annual and monthly goals through effective donor recruitment. Achieve recruitment objectives by developing market penetration plans, recruitment strategies, to increase blood donations. **What to Expect:** **Schedule:** Monday - Friday Days, occasional evenings, and weekends. Our comprehensive total rewards support you, your family, and your future with: Medical, dental, and vision insurance, 401K + 5 percent company match, Tuition assistance up to \$5k per year, Free basic life and AD&D insurance, Free short-and-long-term disability insurance, Paid time off, Employee Resource Groups, and Recognition and perks. **As a Recruitment Manager, you'll get to:** Be innovative in developing special recruitment programs to address business needs. Assist in implementing strategic marketing plans, territory alignment, and goal setting. Monitor center resource allocation and scheduling. Build relationships with both internal staff and customers to maintain goal objectives. Ensure adherence to recruitment processes. Please click [here](#) to apply.

Medical Director. OneBlood, a nationally recognized blood center collecting over one million donations annually, is seeking an experienced, board-certified Blood Center **Medical Director**. This physician leader will join

(continued on page 11)

POSITIONS (continued from page 10)

our team of Transfusion Medicine experts and play a pivotal role in advancing donor and patient safety, transfusion services, therapeutic apheresis, and research collaborations. Our position, located in the state of Florida, includes a competitive salary & benefits package, performance incentives, retirement plan with company contribution plus a company match, vehicle stipend, company-paid holidays, much more. Qualifications include a MD or DO degree, valid/current Florida Medical Doctor license, a minimum of one year of transfusion medicine experience, as well as board subspecialty certification in Blood Banking/Transfusion Medicine recognized by the American Board of Pathology (ABP) or equivalent, required. For a complete listing of required qualifications and job description and to apply, visit our *Careers* page at www.oneblood.org and search Medical Director to learn more.

Vice President, Blood Services (Eastern and Western Area - Remote). Vitalant is looking for a bold, visionary leader to join our Blood Services Leadership Team as the **Vice President, Eastern Area**. This is a high-impact role, that will focus on deep community and customer engagement, mobile blood drive success, resource management for both mobile and fixed sites, with local facility and fleet oversight. This position works in a highly collaborative manner with leadership throughout the organization to ensure strategic and collection goals are met. **We're Looking for a Proven Senior Leader Who Can:** Translate enterprise strategy into local execution. Build and lead high-performing teams of senior and mid-level leaders. Cultivate a culture of accountability, learning, and cross-functional partnership. Balance operational excellence with innovation and adaptability. Inspire trust, transparency, and connection across regions and stakeholder groups. **What You Can Expect:** In this high-impact leadership role, you'll receive a competitive compensation and total rewards package including a robust performance-based bonus plan—reflecting your years of experience and the vital influence this position has on our mission and long-term success. If you're ready to make a measurable impact on public health through quality leadership, we invite you to join us. Interested applicants www.vitalant.org/careers.

Associate Medical Director/Medical Director. Serve as the physician face of Versiti and Versiti Ohio, translating complex medical issues to educate other physicians, support staff and the public. Opportunities in educational initiatives and clinical/applied research are available within Versiti and with our affiliated health systems. As part of the Versiti physician team you will have the opportunity to participate in clinical research projects with investigators at our world-renowned diagnostic laboratory and blood research institute. Joining our Medical Science Institute transfusion medicine physician team will provide you with a uniquely diverse and collaborative experience. Requirements: MD or DO Degree. Board certified/eligible in Blood Banking/Transfusion Medicine. At least three years of experience in blood center/transfusion medicine practice preferred. Licensed or eligible for an Ohio and Indiana; other state licenses may be required. Driver's License in good standing. Please click [here](#) to read the full job description and apply. 💧